Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.

Owley T, Salt J, Guter S, Grieve A, Walton L, Ayuyao N, Leventhal BL, Cook EH Jr.

J Child Adolesc Psychopharmacol. 2006 Oct;16(5):517-24.

PMID:
17069541
2.

Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.

Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ.

J Child Adolesc Psychopharmacol. 2006 Oct;16(5):599-610.

PMID:
17069548
3.

Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.

Wake R, Miyaoka T, Inagaki T, Furuya M, Ieda M, Liaury K, Kishi K, Horiguchi J.

J Child Adolesc Psychopharmacol. 2013 Jun;23(5):329-36. doi: 10.1089/cap.2012.0108.

PMID:
23782127
4.

A retrospective study of memantine in children and adolescents with pervasive developmental disorders.

Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ.

Psychopharmacology (Berl). 2007 Mar;191(1):141-7. Epub 2006 Oct 3.

PMID:
17016714
5.

Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.

Schulz JB, Rainer M, Kl√ľnemann HH, Kurz A, Wolf S, Sternberg K, Tennigkeit F.

J Alzheimers Dis. 2011;25(3):463-75. doi: 10.3233/JAD-2011-101929.

PMID:
21471647
6.
7.

A Prospective Open-Label Trial of Memantine Hydrochloride for the Treatment of Social Deficits in Intellectually Capable Adults With Autism Spectrum Disorder.

Joshi G, Wozniak J, Faraone SV, Fried R, Chan J, Furtak S, Grimsley E, Conroy K, Kilcullen JR, Woodworth KY, Biederman J.

J Clin Psychopharmacol. 2016 Jun;36(3):262-71. doi: 10.1097/JCP.0000000000000499.

PMID:
27043118
8.

The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia.

Cheon Y, Park J, Joe KH, Kim DJ.

Int J Neuropsychopharmacol. 2008 Nov;11(7):971-83. doi: 10.1017/S1461145708008663. Epub 2008 Mar 17.

PMID:
18346293
9.

Open-label memantine in fragile X syndrome.

Erickson CA, Mullett JE, McDougle CJ.

J Autism Dev Disord. 2009 Dec;39(12):1629-35. doi: 10.1007/s10803-009-0807-3. Epub 2009 Jul 16.

PMID:
19609663
10.

Risperidone monotherapy in preschool children with pervasive developmental disorders.

Masi G, Cosenza A, Mucci M, De Vito G.

J Child Neurol. 2001 Jun;16(6):395-400.

PMID:
11417603
11.

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.

Research Units on Pediatric Psychopharmacology Autism Network.

Arch Gen Psychiatry. 2005 Nov;62(11):1266-74.

PMID:
16275814
12.

Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study.

Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, Tsuchie K, Inagaki T, Horiguchi J.

BMC Psychiatry. 2012 Nov 29;12:215. doi: 10.1186/1471-244X-12-215.

13.

Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.

Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ.

J Child Neurol. 2004 Mar;19(3):165-9.

PMID:
15119476
14.

Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation.

Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH.

J Child Adolesc Psychopharmacol. 1997 Summer;7(2):109-21.

PMID:
9334896
15.

An open-label trial of escitalopram in pervasive developmental disorders.

Owley T, Walton L, Salt J, Guter SJ Jr, Winnega M, Leventhal BL, Cook EH Jr.

J Am Acad Child Adolesc Psychiatry. 2005 Apr;44(4):343-8.

PMID:
15782081
16.

Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.

Pomara N, Ott BR, Peskind E, Resnick EM.

Alzheimer Dis Assoc Disord. 2007 Jan-Mar;21(1):60-4.

PMID:
17334274
17.

A pilot open label prospective study of memantine monotherapy in adults with ADHD.

Surman CB, Hammerness PG, Petty C, Spencer T, Doyle R, Napolean S, Chu N, Yorks D, Biederman J.

World J Biol Psychiatry. 2013 May;14(4):291-8. doi: 10.3109/15622975.2011.623716. Epub 2012 Mar 22.

PMID:
22436083
18.

The usefulness of the Revised Psychoeducational Profile for the assessment of preschool children with pervasive developmental disorders.

Portoghese C, Buttiglione M, Pavone F, Lozito V, De Giacomo A, Martinelli D, Margari L.

Autism. 2009 Mar;13(2):179-91. doi: 10.1177/1362361308100687.

PMID:
19261687
19.

Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study.

Troost PW, Althaus M, Lahuis BE, Buitelaar JK, Minderaa RB, Hoekstra PJ.

J Child Adolesc Psychopharmacol. 2006 Oct;16(5):561-73.

PMID:
17069545
20.

Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.

Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I.

Dement Geriatr Cogn Disord. 2007;23(5):301-6. Epub 2007 Mar 13.

PMID:
17356273

Supplemental Content

Support Center